Document Detail


Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
MedLine Citation:
PMID:  18757091     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The BEAUTIFUL study assessed the morbidity and mortality benefits of the heart rate-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large cohort of patients with stable coronary artery disease and left-ventricular dysfunction. We did a subanalysis of this placebo group to test the hypothesis that elevated resting heart rate at baseline is a marker for subsequent cardiovascular death and morbidity. METHODS: The association of baseline resting heart rate with cardiovascular outcomes was analysed using Cox proportional hazard models for groups with a heart rate of 70 beats per min (bpm) or greater (2693 patients) versus less than 70 bpm (2745 patients). Additional analyses were done with finer categorisation of heart rate, and with heart rate as a continuous variable. FINDINGS: After adjustment for baseline characteristics, patients with heart rates of 70 bpm or greater had increased risk for cardiovascular death (34%, p=0.0041), admission to hospital for heart failure (53%, p<0.0001), admission to hospital for myocardial infarction (46%, p=0.0066), and coronary revascularisation (38%, p=0.037). For every increase of 5 bpm, there were increases in cardiovascular death (8%, p=0.0005), admission to hospital for heart failure (16%, p<0.0001), admission to hospital for myocardial infarction (7%, p=0.052), and coronary revascularisation (8%, p=0.034). The analysis of fine-groupings of heart rate suggests that the increase in mortality and heart failure outcomes rises continuously above 70 bpm, whereas the relation is less pronounced for coronary outcomes. For heart failure outcomes, the predictive value of resting heart rate was stronger for earlier events than for later events. INTERPRETATION: In patients with coronary artery disease and left-ventricular systolic dysfunction, elevated heart rate (70 bpm or greater) identifies those at increased risk of cardiovascular outcomes, with a differential effect on outcomes associated with heart failure and outcomes associated with coronary events.
Authors:
Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari;
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-08-29
Journal Detail:
Title:  Lancet     Volume:  372     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-08     Completed Date:  2008-09-19     Revised Date:  2009-04-10    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  817-21     Citation Subset:  AIM; IM    
Affiliation:
Royal Brompton Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Benzazepines / pharmacology*,  therapeutic use
Cardiovascular Diseases / etiology*,  mortality,  prevention & control
Coronary Disease / complications*
Female
Heart Rate / drug effects*
Humans
Male
Middle Aged
Prognosis
Proportional Hazards Models
Risk Factors
Tachycardia / complications,  drug therapy
Ventricular Dysfunction, Left / complications*
Chemical
Reg. No./Substance:
0/Benzazepines; 155974-00-8/ivabradine
Comments/Corrections
Comment In:
Curr Hypertens Rep. 2009 Feb;11(1):45-7   [PMID:  19146800 ]
Lancet. 2008 Sep 6;372(9641):779-80   [PMID:  18757092 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial...
Next Document:  The responses of osteoblasts, osteoclasts and endothelial cells to zirconium modified calcium-silica...